These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 20466440)

  • 1. Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response.
    Kovalchin J; Krieger J; Genova M; Collins K; Augustyniak M; Masci A; Hittinger T; Kuca B; Edan G; Braudeau C; Rimbert M; Patel U; Mascioli E; Zanelli E
    J Neuroimmunol; 2010 Aug; 225(1-2):153-63. PubMed ID: 20466440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis.
    Broadley SA; Vanags D; Williams B; Johnson B; Feeney D; Griffiths L; Shakib S; Brown G; Coulthard A; Mullins P; Kneebone C
    Mult Scler; 2009 Mar; 15(3):329-36. PubMed ID: 19039022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4.
    Basile E; Gibbs E; Aziz T; Oger J
    J Neuroimmunol; 2006 Aug; 177(1-2):161-6. PubMed ID: 16765453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
    Wolinsky JS; Narayana PA; O'Connor P; Coyle PK; Ford C; Johnson K; Miller A; Pardo L; Kadosh S; Ladkani D;
    Ann Neurol; 2007 Jan; 61(1):14-24. PubMed ID: 17262850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis.
    Ehrenreich H; Fischer B; Norra C; Schellenberger F; Stender N; Stiefel M; Sirén AL; Paulus W; Nave KA; Gold R; Bartels C
    Brain; 2007 Oct; 130(Pt 10):2577-88. PubMed ID: 17728357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
    Krapf H; Morrissey SP; Zenker O; Zwingers T; Gonsette R; Hartung HP;
    Neurology; 2005 Sep; 65(5):690-5. PubMed ID: 16157900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
    Janiec K; Wajgt A; Kondera-Anasz Z
    Med Sci Monit; 2001; 7(1):93-8. PubMed ID: 11208501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological studies of mitoxantrone in primary progressive MS.
    Pelfrey CM; Cotleur AC; Zamor N; Lee JC; Fox RJ
    J Neuroimmunol; 2006 Jun; 175(1-2):192-9. PubMed ID: 16644023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a.
    Dubois B; Leary SM; Nelissen I; Opdenakker G; Giovannoni G; Thompson AJ
    J Neurol; 2003 Sep; 250(9):1037-43. PubMed ID: 14504963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glatiramer acetate treatment in PPMS: why males appear to respond favorably.
    Wolinsky JS; Shochat T; Weiss S; Ladkani D;
    J Neurol Sci; 2009 Nov; 286(1-2):92-8. PubMed ID: 19426995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, pharmacokinetic, and pharmacodynamic evaluations of PI-2301, a potent immunomodulator, in a first-in-human, single-ascending-dose study in healthy volunteers.
    Kovalchin J; Krieger J; Collins K; Genova M; Augustyniak M; Masci A; Avril T; Gandon G; Patat A; Fauchoux N; Toutin C; Lacoste E; Patel U; Mascioli E; Zanelli E
    J Clin Pharmacol; 2011 May; 51(5):649-60. PubMed ID: 20940336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
    Bar-Or A; Vollmer T; Antel J; Arnold DL; Bodner CA; Campagnolo D; Gianettoni J; Jalili F; Kachuck N; Lapierre Y; Niino M; Oger J; Price M; Rhodes S; Robinson WH; Shi FD; Utz PJ; Valone F; Weiner L; Steinman L; Garren H
    Arch Neurol; 2007 Oct; 64(10):1407-15. PubMed ID: 17698695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial.
    Achiron A; Kishner I; Sarova-Pinhas I; Raz H; Faibel M; Stern Y; Lavie M; Gurevich M; Dolev M; Magalashvili D; Barak Y
    Arch Neurol; 2004 Oct; 61(10):1515-20. PubMed ID: 15477504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TH1/TH2 serum cytokine profiles and soluble TNF-receptor response in patients with chronic hepatitis C during recombinant human interleukin-12 (rHuIL-12) treatment.
    Teuber G; Rossol S; Lee JH; Dietrich CF; Zeuzem S
    Z Gastroenterol; 2002 Jul; 40(7):487-95. PubMed ID: 12122596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-weekly 22microg subcutaneous IFN-beta-1a in secondary progressive MS: a 3-year follow-up study on brain MRI measurements and serum MMP-9 levels.
    Wu X; Kuusisto H; Dastidar P; Huhtala H; Nikkari ST; Ukkonen M; Höyhtyä M; Elovaara I
    Acta Neurol Scand; 2007 Jul; 116(1):43-8. PubMed ID: 17587254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.